The unmet needs in the erectile dysfunction market
20%
ED impacts around 20% of
men globally across all age brackets1
50%
Approximately half of all men over 40 experience ED2
25%
Around 25% of new diagnoses are in men under 403
Prior to Eroxon®, existing treatments for ED were available only on prescription in most countries around the world, creating barriers to access5. Embarrassment, denial, reticence, cost of a consultation and lack of awareness may prevent someone seeking the help of a doctor or healthcare practitioner. Men with ED whose sexual partners wish to be supportive and solutions-oriented are doubly hindered by these factors as up until the launch of Eroxon® only the sufferer could be prescribed the treatment. Oral treatments can also have systemic side effects and cannot be taken in combination with several medications.
Eroxon® and its new formulation Eroxon® Intense offers a different approach. As a fast-acting, topical treatment available over the counter, Eroxon® can be used in the moment and integrated into intimacy, including as part of foreplay. This enables a more natural, less medical experience that supports both partners. Positioned as a first-step, particularly for men with mild to moderate or occasional ED, Eroxon® occupies a distinct space in the category - bridging efficacy, spontaneity, and a more experience-led approach to sexual health.
50%
Approximately half of all men with ED do not discuss their condition with their doctor6